Back to today’s briefing

Story perspectives

Study Reveals Ovarian Cancer's Deadly Genome Doubling Impact

7/18/2025

40 7

Summary

Story summary

A groundbreaking study from Memorial Sloan Kettering Cancer Center uncovers that over 65% of high-grade serous ovarian carcinoma tumors undergo whole-genome doubling (WGD). This genetic alteration not only boosts resistance to treatments but also dampens immune responses, highlighting an urgent need for targeted therapies that can effectively tackle WGD and enhance patient outcomes.

1 of 1

Story summary

A groundbreaking study from Memorial Sloan Kettering Cancer Center uncovers that over 65% of high-grade serous ovarian carcinoma tumors undergo whole-genome doubling (WGD). This genetic alteration not only boosts resistance to treatments but also dampens immune responses, highlighting an urgent need for targeted therapies that can effectively tackle WGD and enhance patient outcomes.